The neurosteroid dehydroepiandrosterone could improve somatic cell reprogramming

Area of Science:

• Stem Cell Biology
• Molecular Biology
• Endocrinology

Background:

• Induced pluripotent stem cells (iPSCs) are generated by reprogramming somatic cells with specific transgenes (Oct4, Sox2, Klf4, c-myc).
• High apoptosis rates, particularly mediated by the p53 pathway, significantly hinder iPSC generation efficiency and clinical translation.
• Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone known to modulate cellular processes, including apoptosis.

Purpose of the Study:

• To investigate the role of DHEA in mitigating apoptosis during the somatic cell reprogramming process.
• To determine if DHEA can enhance the efficiency of induced pluripotent stem cell (iPSC) generation by reducing p53-mediated apoptosis.
• To assess the impact of DHEA on cell viability during reprogramming.

Main Methods:

• Somatic cells were subjected to reprogramming using established protocols involving Oct4, Sox2, Klf4, and c-myc transgenes.
• The effect of DHEA administration on apoptosis levels, specifically via the p53 pathway, was assessed.
• Cell viability and reprogramming efficiency were quantified in the presence and absence of DHEA.

Main Results:

• DHEA treatment was found to decrease apoptosis in somatic cells undergoing reprogramming.
• The inhibitory effect of DHEA on apoptosis was linked to the modulation of the p53 apoptotic pathway.
• DHEA administration led to increased cell viability and improved reprogramming yields for iPSC generation.

Conclusions:

• DHEA effectively reduces apoptosis during somatic cell reprogramming by suppressing the p53 pathway.
• The administration of DHEA enhances the efficiency of induced pluripotent stem cell (iPSC) generation.
• DHEA represents a promising therapeutic strategy to overcome reprogramming barriers and advance iPSC technology for clinical applications.